DE60217300D1 - Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression - Google Patents

Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Info

Publication number
DE60217300D1
DE60217300D1 DE60217300T DE60217300T DE60217300D1 DE 60217300 D1 DE60217300 D1 DE 60217300D1 DE 60217300 T DE60217300 T DE 60217300T DE 60217300 T DE60217300 T DE 60217300T DE 60217300 D1 DE60217300 D1 DE 60217300D1
Authority
DE
Germany
Prior art keywords
integrin expression
angionegesis
hemmer
infringement
investigating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60217300T
Other languages
English (en)
Other versions
DE60217300T2 (de
Inventor
Naoto Ono
Senba
Naoko Hata
Yasuhiro Funahashi
Wakabayashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai Co Ltd
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of DE60217300D1 publication Critical patent/DE60217300D1/de
Application granted granted Critical
Publication of DE60217300T2 publication Critical patent/DE60217300T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE60217300T 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression Expired - Lifetime DE60217300T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001044646 2001-02-21
JP2001044646 2001-02-21
PCT/JP2002/001562 WO2002066073A1 (fr) 2001-02-21 2002-02-21 Procede servant a analyser l'effet d'un inhibiteur d'angiogenese medie par l'inhibition de l'expression de l'integrine

Publications (2)

Publication Number Publication Date
DE60217300D1 true DE60217300D1 (de) 2007-02-15
DE60217300T2 DE60217300T2 (de) 2007-10-04

Family

ID=18906601

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60229676T Expired - Lifetime DE60229676D1 (de) 2001-02-21 2002-02-21 Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression
DE60217300T Expired - Lifetime DE60217300T2 (de) 2001-02-21 2002-02-21 Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60229676T Expired - Lifetime DE60229676D1 (de) 2001-02-21 2002-02-21 Verfahren zur Untersuchung der Wirkung eines Angiogenese-Hemmers unter Vermittlung durch Hemmung der Integrin-Expression

Country Status (12)

Country Link
US (1) US7122318B2 (de)
EP (2) EP1742052B1 (de)
JP (1) JP4255285B2 (de)
KR (1) KR20030080013A (de)
CN (2) CN101025419A (de)
AT (2) ATE350660T1 (de)
AU (1) AU2002233677B2 (de)
CA (1) CA2438427C (de)
DE (2) DE60229676D1 (de)
ES (2) ES2317368T3 (de)
HK (2) HK1059038A1 (de)
WO (1) WO2002066073A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2317368T3 (es) 2001-02-21 2009-04-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de la integrina.
US20040235866A1 (en) * 2001-09-05 2004-11-25 Takahisa Hanada Lymphocytic activation inhibitor and remedial agent for autoimmune disease
WO2005090297A1 (en) * 2004-03-19 2005-09-29 Biotie Therapies Corporation Sulphonamide derivatives
WO2006090932A1 (ja) * 2005-02-28 2006-08-31 Eisai R & D Managemant Co., Ltd. スルホンアミド化合物の代理マーカー
EP3088400A1 (de) 2005-06-22 2016-11-02 Plexxikon Inc. Pyrrolo[2,3-b]pyridin-derivate als proteinkinasehemmer
FI20055498A0 (fi) * 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
WO2007086605A1 (ja) * 2006-01-27 2007-08-02 Eisai R & D Management Co., Ltd. スルホンアミド化合物の効果を予測する方法
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
PE20211866A1 (es) 2018-10-30 2021-09-21 Gilead Sciences Inc Derivados de quinolina como inhibidores de la integrina alfa4beta7
EP3873897B1 (de) 2018-10-30 2024-08-14 Gilead Sciences, Inc. N-benzoyl-phenylalanin-derivate als alpha4beta7 integrin-inhibitoren zur behandlung von entzündlichen erkrankungen
US11174256B2 (en) 2018-10-30 2021-11-16 Gilead Sciences, Inc. Imidazopyridine derivatives
WO2020092401A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. COMPOUNDS FOR INHIBITION OF ALPHA 4β7 INTEGRIN
WO2021030438A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3545461B2 (ja) * 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
EP0673937B1 (de) * 1993-09-10 2003-11-26 Eisai Co., Ltd. Bicyclische, heterocyclische sulfonamide und sulfonsäureester
ATE203515T1 (de) * 1996-03-29 2001-08-15 Searle & Co Meta-substituierte phenylsulphonamidderivate
AU733303C (en) * 1996-05-31 2002-08-08 Scripps Research Institute, The Methods and compositions useful for inhibition of angiogenesis
AU724216B2 (en) * 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6291503B1 (en) * 1999-01-15 2001-09-18 Bayer Aktiengesellschaft β-phenylalanine derivatives as integrin antagonists
JP2000247949A (ja) * 1999-02-26 2000-09-12 Eisai Co Ltd スルホンアミド含有インドール化合物
NZ520299A (en) 2000-02-03 2004-05-28 Eisai Co Ltd Integrin expression inhibitors containing sulphonamide derivatives
ES2317368T3 (es) 2001-02-21 2009-04-16 EISAI R&D MANAGEMENT CO., LTD. Metodo para evaluar el efecto de un inhibidor de la angiogenesis a traves de la inhibicion de la expresion de la integrina.

Also Published As

Publication number Publication date
EP1742052A1 (de) 2007-01-10
US7122318B2 (en) 2006-10-17
HK1059038A1 (en) 2004-06-18
DE60229676D1 (de) 2008-12-11
EP1362601A4 (de) 2005-07-06
EP1362601B1 (de) 2007-01-03
CA2438427A1 (en) 2002-08-29
AU2002233677B2 (en) 2005-01-06
KR20030080013A (ko) 2003-10-10
JPWO2002066073A1 (ja) 2004-06-17
ATE412895T1 (de) 2008-11-15
WO2002066073A1 (fr) 2002-08-29
HK1099363A1 (en) 2007-08-10
CN100384482C (zh) 2008-04-30
EP1362601B8 (de) 2007-02-28
ATE350660T1 (de) 2007-01-15
CN101025419A (zh) 2007-08-29
CA2438427C (en) 2011-04-12
ES2317368T3 (es) 2009-04-16
CN1620313A (zh) 2005-05-25
EP1362601A1 (de) 2003-11-19
EP1742052B1 (de) 2008-10-29
DE60217300T2 (de) 2007-10-04
ES2280502T3 (es) 2007-09-16
US20040132783A1 (en) 2004-07-08
JP4255285B2 (ja) 2009-04-15

Similar Documents

Publication Publication Date Title
DE60217300D1 (de) Verfahren zur untersuchung der wirkung eines angionegesis-hemmers unter vermittlung durch hemmung der integrin-expression
Warren Nasal emission of air and velopharyngeal function
ATE404890T1 (de) Verfahren und vorrichtung zur schnellen tomographischen messung der elektrischen leitfähigkeitsverteilung in einer probe
WO2005091893A3 (en) System for high dynamic range analysis in flow cytometry
FI20000417A0 (fi) Ihmiseen liittyvä mittausarviointi
DE60010224D1 (de) Vorrichtung, computersystem und computerprogramm zur bestimmung eines kardiovasculären parameters
ATE207609T1 (de) Verfahren und vorrichtung zur überprüfung eines sensors
ATE427067T1 (de) Verfahren zur detektierung von temperaturanderungen
DE60300331D1 (de) Dynamischer vergleich von artefakten
CN101512011A (zh) 在生物介质中测定酶活性的方法
DE50107758D1 (de) Vorrichtung zur kontrolle der energie und/oder der position eines gepulsten und gescannten laserstrahls
BRPI0409092A (pt) métodos para medir densidade, para deformar uma imagem de um furo de sondagem, e para efetuar registro de densidade
McFarlane et al. Estimating striae of Retzius periodicity nondestructively using partial counts of perikymata
Kirby et al. Sample size estimation using repeated measurements on biomarkers as outcomes
Bechtold et al. Comparison of field methods and models to estimate mean crown diameter
DE60112949D1 (de) Verfahren zum nachweis eines lipoprotein-akutphaseprotein-komplexes
ATE335434T1 (de) Vorrichtung und verfahren zur messung der vaskulären impedanz
ATE463671T1 (de) Verfahren und vorrichtung zur messung der einspritzmenge und der einspritzrate eines einspritzventils für flüssigkeiten
DE602004027399D1 (de) Verfahren und vorrichtung zum testen eines objekts mit ultraschall
DE60203524D1 (de) Verfahren zur messung des arteriolendrucks
DE602008006604D1 (de) Verfahren zur verarbeitung von spaltkammermesssignalen
DE60104327D1 (de) Verfahren und vorrichtung zur in-line-messung von laserpulsen und verfahren zur messung mittels photoakustischer spektroskopie
DE50009357D1 (de) Verfahren zur bestimmung der belastbarkeit eines menschen
ATE205942T1 (de) Verfahren und vorrichtung zur messung der strahlungstiefe einer strahlung
Shen et al. Assessment of microleakage of restorative materials by a diffusion model

Legal Events

Date Code Title Description
8364 No opposition during term of opposition